Rising costs may not be a result of orphan drugs

Published Online: Sep 12,2016 Laurie Toich, Assistant Editor From Daraprim’s price rising 5556% by Turing Pharmaceuticals under the leadership of Martin Shkreli, to the most recent pricing scandal with Mylan’s EpiPen, Americans have been faced with high out-of-pocket costs for many prescription drugs. Government institutions, such as the US Centers for Medicare and Medicaid, have begun crafting novel ways to reduce …

Rare diseases

Sharing the mission to conquer rare diseases

Closer collaboration between pharmaceutical companies and patient organizations will accelerate drug development At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases. Advocacy groups rely on their partners for financial and scientific support while providing access to repositories of patient data – the key to understanding rare diseases …

An insight into NIH’s Big Data to Knowledge project

DNAdigest– official supporter of BioData World Congress USA, interviewed Phil Bourne – Associate Director for Data Science at the National Institutes of Health about the Big Data to Knowledge (BD2K) project. What is Big Data to Knowledge (BD2K)? “BD2K is an NIH program across 27 institutes of about 110 million dollars a year. The program focus is on the challenges emerging in data across biosciences, …

Interview: Veterans Affairs Precision Oncology Project

Our supporting partner DNAdigest got in touch with one of our speakers at BioData World Congress– Louis Fiore, doctor, scientist, manager, innovator at the Department of Veterans Affairs (VA) in Boston Massachusetts, Executive Director of the Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC). Louis will be speaking about the Precision Oncology Project at BioData World Congress USA 2016. We want to share some …

Abbot Laboratories Whitepaper

Whitepaper: Considerations in Purchasing a LIMS

Randy C. Hice | Abbot Laboratories Many scientific enterprises find themselves in need of a Laboratory Information Management System (LIMS) to replace an incumbent system, whether an existing commercial application, an amalgam of systems, or an in-house solution. Once the decision has been made, the selection and deployment of a new LIMS should move quickly and decisively. This white paper …

New uses for Cord Blood as an immunotherapy - will be covered at the Cord Blood World Europe Congress, 20-21 May in London at the Business Design Centre

New uses for Cord Blood as an immunotherapy and in the treatment of lysosomal storage disease

Dr Jaap Boelens, Pediatric Oncologist at the University of Utrecht has also been working on developing multiple treatments using cord blood. One of which involves using cord blood transplants to improve the outcomes of an immunotherapy (Dendritic Cell Vaccination) which will go into the clinic later this year. He will be discussing his findings at the Cord Blood World Europe Congress in …

Out with the old for cancer treatment?

Today is #WorldCancerDay and it strikes me that it is great to see all of the developments in cancer treatments within the scientific community. The way in which we develop medicines is changing, and now everywhere you look you see information about ‘personalised’ or ‘precision’ medicine. One of the areas which is being hailed as a key disease group which …

NHS faces backlash over Cancer Drugs Fund treatments changes

NHS England announced this week a decision to reassess 42 drugs that are available as part of the Cancer Drugs Fund. The decision comes as a result of current spending expected to be £100m over the initial budget of £280m for this financial year. With the current system viewed as unsustainable, price caps have been brought in for the first time …